πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 912 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11913027

Methods of treatment using pluripotent human adipose adult stem cells

The Regents of the University of California Β· Granted Tue Feb 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11903967

Method of preparing T cells with increased activity

AUTOLUS LIMITED Β· Granted Tue Feb 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11903973

Genetically engineered hematopoietic stem cells and uses thereof

Vor Biopharma Inc. Β· Granted Tue Feb 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11898166

In vitro generation of thymic organoid from human pluripotent stem cells

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11898165

Engineered host cells and methods of use thereof

MiNK Therapeutics, Inc. Β· Granted Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11891628

Method for biomimetic culture of urothelial cells and uses thereof

China Medical University Β· Granted Tue Feb 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11891626

Isolated discogenic cells, methods of using, and methods of preparing same from mammalian

DiscGenics, Inc. Β· Granted Tue Feb 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11885806

Method for depleting malignant T-cells

AUTOLUS LIMITED Β· Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11883431

T-cells modified to overexpress PHF19

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11885807

Method for depleting malignant T-cells

AUTOLUS LIMITED Β· Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11884932

In vitro production of medial ganglionic eminence precursor cells

The Regents of the University of California Β· Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11866794

Cas-ready mouse embryonic stem cells and mice and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jan 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11865157

Compositions and methods of targeting cancer stem cells

The Board of Regents of the University of Texas System Β· Granted Tue Jan 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11857574

Genetically engineered T cells with Regnase-1 and/or TGFBRII disruption have improved func

CRISPR THERAPEUTICS AG Β· Granted Tue Jan 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11858884

Compositions and methods for modulating gene or gene product in cells

The Board of Regents of the University of Texas System Β· Granted Tue Jan 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11851680

Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)

Precision BioSciences, Inc. Β· Granted Tue Dec 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11851677

Composition and methods for inducing myeloid suppressive cells and use thereof

Fate Therapeutics, Inc. Β· Granted Tue Dec 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11850261

Methods of producing human RPE cells and pharmaceutical preparations of human RPE cells

Astellas Institute for Regenerative Medicine Β· Granted Tue Dec 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11851672

CAR T-cells comprising transcriptional circuits

AUTOLUS LIMITED Β· Granted Tue Dec 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11839631

Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progeni

United Therapeutics Corporation Β· Granted Tue Dec 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11840575

Engineered immune cells targeting BCMA and their uses thereof

GRACELL BIOTECHNOLOGIES (SHANGHAI) CO., LTD. Β· Granted Tue Dec 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11839596

Treatment of vasculopathy with prostacyclin and mesenchymal stem cells

United Therapeutics Corporation Β· Granted Tue Dec 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11801265

Preparation method of NK cells and use thereof in the treatment of cancer

SINO UNITED (BEIJING) BIOMEDICAL TECHNOLOGY CO., LTD. Β· Granted Tue Oct 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11802272

Enrich and amplify highly potent human mesenchymal stem cells from elderly cell population

The Board of Regents of the University of Texas System Β· Granted Tue Oct 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted